Document is current
Any future updates will be listed below
-
Authors
Yang, Ting
Lin, Zhi-Rui https://orcid.org/0009-0004-5340-0574
Xia, Tian-Liang https://orcid.org/0009-0002-3369-8612
Liu, Shang-Xin https://orcid.org/0000-0001-9915-9190
Yuan, Bo-Yu
Luo, Yi-Ling
Du, Wen-Ting
Lei, Chao-Bo https://orcid.org/0009-0003-5456-803X
Nie, Yong-Zhan https://orcid.org/0000-0003-1124-4548
Zeng, Mu-Sheng https://orcid.org/0000-0003-3509-5591
Zhong, Qian https://orcid.org/0000-0003-1071-6996
- License Information
-
More Information
Article History
Received: 6 August 2024
Revised: 20 May 2025
Accepted: 12 June 2025
First Online: 5 July 2025
Competing interests
: Q.Z., M.Z., T.Y., Z.L. and T.X. declare that they hold a pending patent on the application of PLEKHA1-TACC2 in enhancing the anti-tumor efficacy of EphA2 inhibitors.
: This study was approved by the institutional review board of SYSUCC (approval no. B2022-281, B2024-790-01). Informed consent was obtained from all individual participants. All animals were used in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals, with the approval of Sun Yat-Sen University Cancer Center, Guangzhou (approval no. L025504202204010).
